Figure 8.

In vivo clearance of EB66-produced monoclonal antibodies in mice. BALB/c mice were injected via the retro orbital sinus route with the commercial CHO-produced anti-CD20 rituximab antibody and its counterpart anti-CD20 antibody produced on EB66 cells at 10 mg/kg (A) or 20 mg/kg (B). The antibody concentrations in plasma were monitored using a human IgG-specific ELISA. The serum concentration 5 min after injection is considered as 100%. Data are the mean ± S.D. of four animals per group. The serum half-life of the administrated IgG1 was calculated from the slope of the elimination β-phase.